ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients?

Thromb Res. 2020 Oct:194:176-177. doi: 10.1016/j.thromres.2020.06.041. Epub 2020 Jun 24.

¹ Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy. Electronic address: federico.nichetti@istitutotumori.mi.it.
² Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
³ Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
⁴ Medical Oncology Unit, ASST Bergamo Ovest, 24047 Treviglio, BG, Italy.

No abstract available

Keywords: ALK; Non-Small-Cell Lung Cancer; ROS-1; Thromboembolic events; Thrombosis; Tyrosine kinase inhibitors.

Publication types